Edwards Lifesciences Corp (EW)vsHaemonetics Corporation (HAE)
EW
Edwards Lifesciences Corp
$89.60
+0.88%
HEALTHCARE · Cap: $49.56B
HAE
Haemonetics Corporation
$85.38
-1.62%
HEALTHCARE · Cap: $3.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 388% more annual revenue ($6.51B vs $1.33B). EW leads profitability with a 15.4% profit margin vs 7.3%. HAE appears more attractively valued with a PEG of 1.35. HAE earns a higher WallStSmart Score of 56/100 (C).
EW
Buy55
out of 100
Grade: C
HAE
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.3%
Fair Value
$257.97
Current Price
$89.60
$168.37 discount
Margin of Safety
+33.5%
Fair Value
$86.50
Current Price
$85.38
$1.12 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Earnings expanding 28.4% YoY
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
4.8% revenue growth
Distress zone — elevated risk
7.3% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : HAE
The strongest argument for HAE centers on EPS Growth. PEG of 1.35 suggests the stock is reasonably priced for its growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.2x leaves little room for execution misses.
Bear Case : HAE
The primary concerns for HAE are Revenue Growth, Altman Z-Score, Profit Margin. A P/E of 41.3x leaves little room for execution misses. Debt-to-equity of 1.54 is elevated, increasing financial risk.
Key Dynamics to Monitor
EW profiles as a mature stock while HAE is a value play — different risk/reward profiles.
EW carries more volatility with a beta of 0.85 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
HAE generates stronger free cash flow (53M), providing more financial flexibility.
Bottom Line
HAE scores higher overall (56/100 vs 55/100). EW offers better value entry with a 69.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Haemonetics Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?